Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing | Zendy

Naoki Okumura | Zendy; Yugo Okazaki | Zendy; Ryota Inoue | Zendy; Kazuya Kakutani | Zendy; Shinichiro Nakano | Zendy; Shigeru Kinoshita | Zendy; Noriko Koizumi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing

Author(s) -

Naoki Okumura,

Yugo Okazaki,

Ryota Inoue,

Kazuya Kakutani,

Shinichiro Nakano,

Shigeru Kinoshita,

Noriko Koizumi

Publication year - 2016

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.15-18586

Subject(s) - rho associated protein kinase , ophthalmology , corneal endothelium , cornea , chemistry , intraocular pressure , medicine , andrology , kinase , biochemistry

Ripasudil (Glanatec), a selective rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved as a glaucoma and ocular hypertension treatment in Japan in 2014. The purpose of this study was to investigate the feasibility of using ripasudil eye drops to treat corneal endothelial injuries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research